• Phathom Pharmaceuticals highlighted new clinical research on its acid blocker vonoprazan at Digestive Disease Week 2026, with results already presented during the May 2-5 meeting in Chicago.
• Company-sponsored analyses from its Phase 3 pHalcon-NERD-301 trial showed symptom improvement in non-erosive GERD patients treated with vonoprazan versus placebo, with one poster receiving a Poster of Distinction designation.
• Phathom also presented a Phase 1 lactation study designed to assess vonoprazan levels in breast milk, supporting potential labeling and prescribing discussions for use in nursing patients.
• Independent investigator abstracts at the meeting broadened the evidence base across erosive esophagitis, H. pylori treatment, and longer-term safety versus older acid-suppression drugs, reinforcing commercial positioning for VOQUEZNA across acid-related conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phathom Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605200800PRIMZONEFULLFEED9723608) on May 20, 2026, and is solely responsible for the information contained therein.